(Q37892874)

24 August 2017

1 reference

title

Current and future treatment approaches for neuromyelitis optica (English)

1 reference

24 August 2017

Nicolas Collongues

1

1 reference

ORCID Public Data File 2021

author name string

Jérôme de Seze

series ordinal

2

1 reference

24 August 2017

1 March 2011

1 reference

Therapeutic advances in neurological disorders

24 August 2017

1 reference

24 August 2017

4

1 reference

24 August 2017

2

1 reference

24 August 2017

111-121

1 reference

EFNS guidelines on diagnosis and management of neuromyelitis optica

24 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

CD20-targeted therapy: the next generation of antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Therapeutic potential of complement modulation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Immunomodulatory therapies in neurologic critical care

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Practice parameters and technology assessments: what they are, what they are not, and why you should care

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

BIOLOGICAL ACTIVITIES OF C1 INHIBITOR

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Revised diagnostic criteria for neuromyelitis optica

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Clinical pharmacokinetics of cyclophosphamide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Mechanisms of mitoxantrone in multiple sclerosis--what is known?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Mycophenolate mofetil and its mechanisms of action

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

The clinical course of neuromyelitis optica (Devic's syndrome).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Pharmacokinetics and metabolism of mitoxantrone. A review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Devic disease in a child with primary Sjögren syndrome.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Human autopsy tissue concentrations of mitoxantrone.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Neuromyelitis optica in France: a multicenter study of 125 patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Intermittent plasmapheresis prevents recurrence in neuromyelitis optica

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

An open label study of the effects of rituximab in neuromyelitis optica

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

A case of relapsing neuromyelitis optica treated with glatiramer acetate

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105616

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756285611398939

Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica

21 January 2018

1 reference

12 December 2020

Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)

1 reference

12 December 2020

Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment

1 reference

12 December 2020

Relapsing neuromyelitis optica: long term history and clinical predictors of death

1 reference

12 December 2020

Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies

1 reference

12 December 2020

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

1 reference

12 December 2020

Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses

1 reference

12 December 2020

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

1 reference

12 December 2020

Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination

1 reference

12 December 2020

Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide

1 reference

12 December 2020

Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus

1 reference

12 December 2020

Interferon-beta(1b) treatment in neuromyelitis optica

1 reference

12 December 2020

Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis

1 reference

12 December 2020

Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285611398939

1 reference

24 August 2017

1 reference

PMC publication ID

3105616

24 August 2017

PubMed publication ID

21694808

1 reference

PMC publication ID

3105616